A3 Vertaisarvioitu kirjan tai muun kokoomateoksen osa
PET radiopharmaceuticals for imaging inflammatory diseases
Tekijät: Li Xiang-Guo, Velikyan Irina, Viitanen Riikka, Roivainen Anne
Toimittaja: Alberto Signore
Julkaisuvuosi: 2022
Kokoomateoksen nimi: Nuclear Medicine and Molecular Imaging
Vuosikerta: 3
Aloitussivu: 734
Lopetussivu: 743
ISBN: 978-0-12-822980-4
DOI: https://doi.org/10.1016/B978-0-12-822960-6.00075-2
The early identification and localization of inflammation and infection is crucial for patient care, and positron emission tomography (PET) imaging provides a sensitive and quantitative tool for diagnosing and monitoring treatment efficacy. However, radiopharmaceuticals with better specificity than the currently used glucose analog, 2-Deoxy-2-[18F]fluoro-2-d-glucose ([18F]FDG), are needed to assess inflammation. The purpose of this chapter is to provide an overview of the new PET radiopharmaceuticals available for imaging of inflammatory diseases. This review presents the current status of inflammatory radiopharmaceutical development with emphasis on studies in humans. The chapter describes, inter alia, tracers targeting macrophage receptors (e.g., folate receptor beta, 18 kDa translocator protein [TSPO]), adhesion molecules (e.g., VCAM-1, VAP-1), and phospholipid metabolism.